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Abstract: New first-row transition-metal compounds with the ligand 
norharmane (9H-Pyrido[3,4-b]indole; Hnor) are reported. The compounds 
have the general formula [M(LL)(Hnor)(NO3)2](MeOH)0-1 (M=Co, Ni, Cu, Zn; 
LL = 2,2'-bipyridyl (bpy), 1,10-phenanthroline (phen)) and have been 
characterized by physical and analytical methods. X-ray structural 
analysis revealed that the compound of formula [Cu(phen)(Hnor)(NO3)2], 
(1) has a distorted 6-coordinated octahedrally-based geometry, with a 
planar-based [CuN3O] core, where Cu-L varies between 1.99-2.04 Ȧ and two 
weak axial Cu-O contacts (2.209 and 2.644 Ȧ) from two different nitrates. 
Based on spectroscopic similarities, the other compounds appear to have 
the same or very similar coordination geometries. The compounds showed 
clear cell growth inhibitory effects in two different cancer cell lines 
in vitro, with the copper and zinc complexes being the most toxic and in 
fact almost comparable to cisplatin. Flow-cytometry analysis confirmed 
induction of apoptosis in cancer cells treated with the compounds. 
Interestingly, co-incubation of the cells with metal complexes and CuCl2 
induced an increase in the cytotoxic effects, most likely due to the 
conversion of the metal compounds in the corresponding, and most active, 
copper analogues. 
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Abstract: 
New first-row transition-metal compounds with the ligand norharmane (9H-Pyrido[3,4-
b]indole; Hnor) are reported. The compounds have the general formula 
[M(LL)(Hnor)(NO3)2](MeOH)0-1 (M=Co, Ni, Cu, Zn; LL = 2,2’-bipyridyl (bpy), 1,10-phenanthroline 
(phen)) and have been characterized by physical and analytical methods. X-ray structural analysis 
revealed that the compound of formula [Cu(phen)(Hnor)(NO3)2], (1) has a distorted 6-coordinated 
octahedrally-based geometry, with a planar-based [CuN3O] core, where Cu-L varies between 1.99-
2.04 Ȧ and two weak axial Cu-O contacts (2.209 and 2.644 Ȧ) from two different nitrates. Based on 
spectroscopic similarities, the other compounds appear to have the same or very similar 
coordination geometries. The compounds showed clear cell growth inhibitory effects in two different 
cancer cell lines in vitro, with the copper and zinc complexes being the most toxic and in fact almost 
comparable to cisplatin. Flow-cytometry analysis confirmed induction of apoptosis in cancer cells 
treated with the compounds. Interestingly, co-incubation of the cells with metal complexes and 
CuCl2 induced an increase in the cytotoxic effects, most likely due to the conversion of the metal 
compounds in the corresponding, and most active, copper analogues. 
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Introduction  
The rational design of innovative metal-containing compounds has been a major goal in 
cancer research in recent years. While initially most of the studies have been largely focusing on 
platinum compounds, more recently other noble metals, like gold, osmium and ruthenium have 
attracted attention [1, 2]. Also silver(I) complexes containing various types of ligands, including 
carboxylic acids, amino acids, nitrogen-, phosphorus-, or sulfur-donor ligands, have been prepared 
and studied for their antitumor activity [3, 4]. In fact, some of them exhibit significant in vitro 
antiproliferative properties [3, 4]. Interestingly, for the kinetically more labile first-row transition 
metals, coordination compounds are known that hold great potential as anticancer agent, and 
earlier studies supported their drug design [5-8]. Earlier studies by Sigman in the 1990s [9-13], and 
by Pitié and Meunier [14-16] and several others in recent years [17-23] indicate efficient DNA 
cleavage and cytostatic properties. Such compounds are also reported to display antiangiogenic 
activity [24]. Also, studies by some of us with Cu(II) compounds and tridentate pyridine-based 
ligands have shown very promising results for both DNA cleavage and anticancer activities [25-28]. 
Within this frame, the results by Ruiz et al. hold great promise, and include the group of 
metal compounds named casiopeinas, copper-based coordination complexes with generic structure 
of [Cu(N–N)(O–N)]+ or [Cu(N–N)(O–O)]+ that have proven cytotoxic to cancer cells sensitive or 
resistant to cisplatin, and to xenograph tumors in mice [29, 30], and are now in clinical trials. The 
mode of action for casiopeinas is largely unknown, but it has been suggested that mitochondrial 
permeability transition may be important [31], as well as DNA damage [32] and others [33].  
In general, investigation of first-row transition metal complexes as cytotoxic agents has 
received increasing attention, because of the development of metallodrugs containing endogenous 
metal ions (instead of non-physiological ones, with potentially severe side effects) is attractive. 
Therefore, many studies have been reported during the last 5 years, including those disclosing the 
3D structure of the respective compounds [5, 34, 35]. Nevertheless, the mode of action of such 
metal complexes is still poorly understood; nucleic acids and proteins are likely targets [36-39]. For 
example, Cu(II), Co(II) and Zn(II) complexes featuring the quinolone antibacterial drug flumequine 
and N,N’-donor heterocyclic compounds as ligands have also been demonstrated to be able to 
interact with nucleic acids and serum albumin [40-43]. Instead, cytotoxic Co(III) complexes with 
substituted phenanthrolines have shown weak binding to nucleic acids [40].  
Based on the above-mentioned considerations, in order to design new first-row transition 
metal compounds with enhanced thermodynamic stability in aqueous solution and with possible 
antiproliferative activity, we have selected the ligand norharmane (9H-Pyrido[3,4-b]indole, 
abbreviated as Hnor and depicted in Scheme 1), consisting of a fused-ring heterocyclic compound 
that belongs to the alkaloid family β-carbolines (βCs). This molecule has been known for over 50 
years [44-49], but it is still poorly studied. It has a remote H-bond donor group, in addition to the 
metal binding site, and so far it has only been used to coordinate Ru(II) ions [49] and more recently 
silver(I) ions [50]. In addition to coordination, also other weak forces, like hydrogen bonding and 
intermolecular non-covalent interactions should be taken into account [51-55]. In this respect Hnor 
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appears to have a suitable structure to bind metal compounds, where coordination, H-bonding and 
π-π stacking may act in synergy. Interestingly, so far a wide spectrum of biological, 
psychopharmacological, and toxicological activities have been reported for Hnor, e.g. anticancer 
[56], binding to benzodiazepine receptors [57], inhibition of monoamine oxidase [58], and DNA 
topoisomerase I and II [59]. 
Despite the fact that several known transition-metal compounds display antiproliferative 
properties, the combination of certain metals and different (potentially) intercalating ligand remains 
challenging and worth studying. 
Following our recent promising results with Ag(I) complexes of Hnor [50], we have extended 
here our study to first-row transition metals, and simultaneously added a polypyridine co-ligand, i.e. 
2,2’-bipyridyl (bpy), or 1,10-phenanthroline (phen), which are known to be able to interact with DNA 
and also possess cell-growth inhibition properties [60]. Thus, we report here on the synthesis and 
characterization of eight new coordination compounds containing the ligands Hnor and 1,10-
phenantroline (phen)/2,2'-bipyridyl (bpy) bound to Cu(II), Co(II), Ni(II) and Zn(II) ions (Scheme 1). 
Notably, the NO3- anion was chosen for charge neutrality and as an additional ligand, as this is a 
potentially weakly coordinating anion, and it is at the same time prone to H-bond acceptance. Thus, 
the potentially tridentate anionic ligand NO3- may act in both monodentate and chelating forms to 
complete the metal coordination sphere [61]. X-ray diffraction studies allowed elucidating the 
structure of the copper complex, with phen as co-ligand, 1. 
Some of the obtained compounds were tested for their effects on cell viability against two 
human cancer cell lines, and evaluation of their apoptotic effects was performed by flow-cytometry. 
In order to study transport of the compounds via copper transporters, the effects of addition of “free” 
Cu(II) to the cell culture medium were also evaluated; this is a classical competition experiment to 
assess transport mechanisms [62], but allowed also to relate the observed biological activity to the 
stability of the metal compounds in solution. 
 
 
Scheme 1 – Schematic description of the metal compounds with Hnor and phen/bpy ligands used in 
this study. 
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Experimental Part 
Starting Materials and methods  
Metal nitrate salts were all used as commercially available; tryptophane was obtained as a 
racemic mixture and used as obtained. Other standard laboratory chemicals were used as 
available. Cisplatin was purchased from Sigma. Infrared spectra were recorded as KBr pellets, 
using a Shimadzu IRAffinity-1 spectrometer with a resolution of 4 cm-1. Ligand field spectra were 
performed on solid powders (room T, diffuse reflectance mode) in the range 200-1100 nm. 
Elemental analysis (C,H,N) were performed on a PerkinElmer 2400 Series II CHNS/O system. NMR 
spectra in DMSO solution were recorded using a JEOL-ECP-400 spectrometer.  
Synthesis 
The ligand norharmane (Hnor) was synthesized from tryptophane and formaline  as 
described by us before [55] according to the method of Snyder et al. [53]. Yield: 3.2 g (32%), M.P.= 
199-200 ºC. 1H NMR (400 MHz, DMSO-d6, ppm, 293 K):11.65 (1H, s, NH); 8.94 (1H, s, H1); 
8.35(1H, d (J = 5.1 Hz), H2); 8.22 (1H, d (J = 8.0 Hz), H4); 8.10 (1H, d (J = 5.1 Hz), H7); 7.56 (2H, 
ddd (J = 8.0, 16.8, 7.3 Hz), H3, H6); 7.24 (1H, t (J = 14.6 Hz), H5). Elemental Analysis for C11H8N2 
(%): Calcd. C, 78.55; H, 4.79; N, 16.66. Found C, 78.46; H, 4.71; N, 16.62.  
Transition-metal compounds 1-8 (see Scheme 1) with the ligand Hnor were prepared by 
dissolving the metal salt and Hnor (1:1) in methanol (MeOH) and adding a co-ligand bpy or phen 
(also in the ratio 1:1). A typical recipe is as follows: 2,2’-Bipyridyl/1,10-phenanthroline (1 mmol) was 
added to the solution of metal salts (1 mmol) in MeOH, and after 30 min of stirring, Hnor (1 mmol) 
was added to the mixture and allowed to stir for 12 h and then kept for slow evaporation. The 
crystalline product obtained was washed with CH2Cl2, ether, hexane. The product obtained was 
dissolved in a MeOH/acetonitrile mixture for re-crystallization. 
The new compounds are listed below with their color and elemental analysis and relevant IR 
and UV data.  
Compounds with phen (1,10-phenanthroline) as a co-ligand 
1: C23N6O6H16Cu, Cu(Hnor)(phen)(NO3)2: green, structurally characterized by XRD (see below); 
Calcd. % C 51.54; H, 3.01; N, 15.68. Found: C, 51.18; H, 2.97; N, 15.57. Yield: 0.438 g (74%). FTIR 
(KBr disc, cm-1): 3438, 1635, 1466, 1427, 1385, 1304, 1255, 1034, 849, 723. UV-Vis: Ȝmax (nm) 
(solid): 257, 301, 371, 663. 
3: C23N6O6H16Co: brown; calcd. % C, 51.17; H, 3.58; N, 14.92 (3 + MeOH); C, 50.36; H, 3.70; N, 
14.68; (3 + MeOH + 0.5H2O). Found: C, 50.39; H, 3.41; N, 14.45. Yield: 0.50 g (78%). FTIR (KBr 
disc, cm-1): 3361, 1631, 1462, 1425, 1385, 1292, 1252, 1038, 845, 725. UV-Vis: Ȝmax (nm) (solid): 
272, 374, 527.  
5: C23N6O6H16Ni: yellow-green; calcd. % C, 51.19; H, 3.58; N, 14.92 (5 + MeOH). Found: C, 51.64; 
H, 3.55; N, 14.87. Yield: 0.49 g (87%). FTIR (KBr disc, cm-1): 3382, 1632, 1457, 1426, 1384, 1302, 
1249, 1041, 847, 726. UV-Vis: Ȝmax (nm) (solid): 253, 291, 357, 617. 
7: C23H16N6O6Zn: yellow; calcd. % C, 51.37; H, 3.00; N, 15.63; and C, 50.52; H, 3.13; N. 15.37; (7 + 
0.5 H2O); Found: C, 50.29; H, 3.07; N, 15.89. Yield: 0.48 g (78%). FTIR (KBr disc, cm-1): 3396, 
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1632, 1461, 1427, 1384, 1290, 1250, 1036, 847, 725. 1H NMR (400 MHz, DMSO-d6, ppm, 293 K): 
11.83 (1H, s, NH); 9.17 (1H, d (J = 3.6 Hz)); 8.75 (1H, s);  8.93 (2H, d (J = 8.0 Hz)); 8.32-8.15 (8H, 
m); 7.59 (2H, ddd (8.0, 14.0, 8.0 Hz)); 7.23 (1H, t (J = 14.8 Hz)). 13C NMR (100 MHz, DMSO-d6, 
ppm, 293 K): 149.19, 141.10 140.11, 139.48, 137.65, 133.98, 128.74, 128.27, 127.32, 125.91, 
122.10, 120.39, 119.62, 112.12. 
Compounds with bpy (2,2’-bipyridine) as a co-ligand: 
2: C21H16N6O6Cu: green; calcd. % C, 49.27; H, 3.15; N, 16.42 and C,48.42; H, 3.29, N, 16.13 (2 + 0.5H2O); 
Found: C, 48.42; H, 3.02; N, 16.41. Yield: 0.54 g (85%). FTIR (KBr disc, cm-1): 3431, 1633, 1603, 1574, 1474, 
1443, 1384, 1286, 1253, 829, 772, 730, 634, 420. UV-Vis: Ȝmax (nm) (solid): 281, 358, 656. 
4: C21H16N6O6Co: brown; calcd. % C, 49.72; H, 3.18; N, 16.57 (and C, 48.85; H, 3.32; N, 16.28 (4 + 0.5H2O). 
Found: C, 48.73; H, 3.34; N,16.56. Yield: 0.495 g (77%). FTIR (KBr disc, cm-1): 3418, 1631, 1606, 1565, 1474, 
1451, 1384, 1304, 1248, 826, 767, 733, 631, 422. UV-Vis: Ȝmax (nm) (solid): 246, 258, 358, 504. 
6: C21H16N6O6Ni; Yellow-green; calcd. % C, 49.74; H, 3.18; N, 16.57 and C, 48.43; H, 3.60; N, 16.69 (6 + 
0.5CH3CN +H2O). Found: C, 48.82; H, 3.41; N, 16.96. Yield: 0.51 g (83%). FTIR (KBr disc, cm-1): 3394, 1632, 
1600, 1567, 1474, 1444, 1384, 1302, 1249, 826, 767, 734, 632, 424. UV-Vis: Ȝmax (nm) (solid): 283, 349, 598.  
8: C21H16N6O6Zn: yellow; calcd. % C, 49.09; H, 3.14; N, 16.36. Found: C, 49.03; H, 3.25; N, 16.54. Yield: 
0.464 g (75%). FTIR (KBr disc, cm-1): 3390, 1632, 1608, 1567, 1475, 1442, 1384, 1290, 1249, 827, 767, 733, 
633, 423. 1H NMR (400 MHz, DMSO-d6, ppm, 293 K): 11.80 (1H, s, NH); 8.91 (1H, s); 8.73 (2H, (J = 7.2 Hz)); 
8.33-8.16 (7H, m); 7.81 (2H, s), 7.59 (2H, ddd (8.8, 12.4, 15.2 Hz)); 7.24 (1H, t (J = 15.6 Hz)). 13C NMR (100 
MHz, DMSO-d6, ppm, 293 K): 148.44, 141.47, 140.98, 137.78, 133.97, 128.63, 128.11, 127.18, 122.76, 
122.05, 120.42, 119.56, 112.15. 
X-ray diffraction studies  
 Suitable single crystals of compound [Cu(Hnor)(phen)(NO3)2] 1 were obtained by slow 
evaporation from a mixture of MeOH/acetonitrile. Diffraction and refinement data for compound 1 
are summarized in Table 1. Diffraction data were collected using a Rigaku R-axis diffractometer 
equipped with imaging plate area detector utilizing Mo-Kα radiation (Ȝ= 0.71073 Å) with graphite 
monochromator. The data were collected using ω-scans to a maximum 2θ of 55.0° at 294 K. 
Preliminary orientation matrices, unit cell determination, data reduction and absorption correction 
were performed using CrystalClear package [63]. The data were empirically corrected for Lorentz 
and polarization effects. The structure was solved by direct methods and refined by full-matrix least 
squares on all |F2| data using SHELX package [64]. Aromatic hydrogen atoms were isotropically 
refined and constrained to ideal geometry, using their appropriate riding model and non-hydrogen 
atoms were anisotropically refined. The Hnor hydrogen atom on N involved in hydrogen bonding 
was located from difference Fourier map and refined with distance restraint. One of the nitrate 
oxygen atoms was found disordered over two positions and refined with a split-atom model of 
0.54/0.46 occupancy factor. The descriptive crystallographic figures were created using the 
DIAMOND package [65]. All relevant crystallographic data are summarized in Table 1. Powder X-
ray diffraction of the Cu(II) phen compound (1) have shown a homogenous phase compared to the 
pattern simulated from the single-crystal diffraction.  
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Table 1. Crystallographic and refinement data for the compound [Cu(Hnor)(phen)(NO3)2]1. 
Compound formula C23H16N6O6Cu 
Formula weight 535.97 
Temperature [K] 294 K 
Crystal system Monoclinic 
Space group C2/c 
a [Å] 31.3912(8) 
b [Å] 8.0795(2) 
c [Å] 23.9514(5) 
β [°] 130.878(1)  
Volume [Å3] 4593.1(2) 
Z 8 
Calculated density [mg/mm3] 1.550 
Absorption coefficient [mm-1] 1.004 
F(000) 2184 
Radiation wavelength 0.71073 
Θ range for data collection [°] 3.1, 27.5 
Index ranges -40: 40 ; -10: 10 ; -30: 30 
Reflections collected 85470 
Independent reflections 4126 
Data/restraints/parameters 5263/1/339 
Goodness-of-fit on F2 1.00 
Final R indexes [I>=2σ(I)] 5.2 
Final R indexes (all data) 14.53 
Largest diff. peak/hole [e Å-3] 0.47/-0.60 
 
Cell viability assay  
The human lung cancer A549 and human ovarian cancer A2780 cell lines, (obtained from 
the European Centre of Cell Cultures ECACC, Salisbury, UK) were cultured in DMEM (A549) and 
RPMI (A2780) complete medium, containing GlutaMax-I and supplemented with 10% FBS and 1% 
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penicillin/streptomycin (all from Invitrogen), at 37 °C in a humidified atmosphere of 95% of air and 
5% CO2 (Heraeus, Germany). For evaluation of growth inhibition, cells were seeded in 96-well 
plates (Costar, Integra Biosciences, Cambridge, MA) at a concentration of 10000 cells/well and 
grown for 24 h in complete medium. Solutions of the compounds were prepared by diluting a freshly 
prepared stock solution (10-2 M in DMSO) of the corresponding compound in aqueous media (RPMI 
or DMEM depending on the cell lines). Stock solutions of the compounds were stable over several 
hours. The percentage of DMSO in the culture medium never exceeded 0.2%: at this concentration 
DMSO has no effect on the cell viability. Afterwards, the intermediate dilutions of the compounds 
were added to the wells (200 ȝL) to obtain a final concentration ranging from 0 to 200 ȝM, and the 
cells were incubated for 24 h or 72 h. Following drug exposure, 3 (4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added to the cells at a final concentration of 0.50 mg.ml-1 
incubated for 3-4 h, time after which the solution was removed and the violet formazan crystals 
dissolved in DMSO. The optical density of each well (96-well plates) was quantified in quadruplicate 
at 550 nm, using a multi-well plate reader, and the percentage of surviving cells was calculated from 
the ratio of absorbance between treated and untreated cells. The IC50 value was calculated as the 
concentration reducing the proliferation of the cells by 50% and is presented as a mean (± SE) of at 
least three independent experiments. Statistical comparisons were based on a two-way paired t-
test. Before conducting the t-test, the normality of the dataset was checked using a Q-Q plot and a 
histogram and homogeneity of the variance was assessed using a Barlett’s test [66].  
Flow Cytometry assays 
Confluent A549 cells were seeded at a density of 50000 cells/well in 24-well flat-bottom cell 
culture plates, under standard conditions for 24 h. Afterwards, the medium was substituted by 
medium containing the appropriate concentrations of compounds, as described above for MTT 
detection. After 72 h incubation, cells were detached and collected by centrifugation. An apoptosis 
Annexin V-APC/PI detection kit (eBiosciences, San Diego, USA) was used to analyze cell 
apoptosis, according to manufacturer’s provided protocol. In short, after centrifugation cells were 
resuspended in binding buffer and stained with APC-conjugated Annexin V, for 15 min at room 
temperature, protected from light. 
Afterwards, cells were stained with propidium iodide (PI) and immediately analyzed by FACS 
(BD FACS arrayTM, BD Bioscience, San Jose, USA). Corresponding data were analyzed using the 
FlowJo software (FlowJo, Ashland, USA). The results shown are representative of at least three 
independent experiments. Viable cells with intact membranes exclude PI, whereas the membranes 
of dead or damaged cells are permeable to PI while Annexin V binds to phosphatidylserine, a 
protein expressed in the extracellular side of the cell membrane of cells undergoing apoptosis. 
Thus, cells that stain positive for Annexin V and negative for PI are undergoing apoptosis in an early 
stage, while cells staining positive for both Annexin V and PI are either in a later stage of apoptosis 
or necrosis. Cells staining positive for only PI are either in a late apoptotic/necrotic or dead and cells 
negative for both Annexin V and PI are alive and not undergoing measurable apoptosis/necrosis. 
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UV-vis spectrophotometry in solution  
 Dilutions of each metal compound were obtained from freshly prepared stock solution (10-2 
M in DMSO) and added to a 96-well plate. To these solutions, either CuCl2 (from a stock solution of 
10-1 M in MiliQ water) or MilliQ water were added. The final ratio of compound versus CuCl2 was 1:4. 
The absorption spectra were recorded between 300-900 nm by spectrophotometry (Synergy H1 
Hybrid reader, BioTek®) at various time points over 24 h at 37 °C. Obtained values were corrected 
for two baselines, with and without CuCl2. 
Results and discussion  
Synthesis and characterization 
The new compounds all have the formulae [M(LL)(Hnor)(NO3)2].The compounds have been 
prepared by dissolving the metal nitrate, LL and Hnor (ratio 1:1:1) in MeOH according to the 
procedure reported in the experimental section.  
Within a few days single-phase crystalline materials were obtained in yields of ~70-80 %, 
from which suitable crystals were selected for X-ray diffraction analysis in the case of Cu and phen. 
The compounds were also characterized by IR and elemental analysis (see Experimental section 
for details). The IR spectra were all found to be quite similar, and (some representative examples) 
are depicted in Figures S1-S8. The coordinated nitrate has typical IR bands around 1300 cm-1 and 
agrees with a monodentate and a bidentate nitrate [67]. The N-H peak of the Hnor ligand is 
generally observed at 3400 +/- 40 cm-1, in some cases split, which is a shift to lower wave numbers 
compared to the free ligand, as a result of N-H---O hydrogen bonding; such hydrogen bonds do 
slightly vary from metal to metal. In the case of compound 2, [Cu(bpy)(Hnor)](NO3)2, the NH pattern 
differs, which may be an indication for a different type of hydrogen bonding. Regretfully, no crystals 
suitable for X-ray diffraction could be found in this case. Bands due to MeOH could not be assigned. 
For further characterization of the compounds for which no single crystals could be grown, 
ligand field spectra of all Cu, Co and Ni compounds have been recorded in the diffuse reflectance 
mode. The spectra as such are as expected and are in accordance with octahedrally-based 
geometries for the metal ions [68]. The Cu compounds have, apart from CT bands above 26000 
cm-1, LF maxima at 16000 cm-1 (compound 1) and 16200 cm-1 (compound 2), typical for tetragonal 
Cu(II). The Co(II) compounds also shows the CT bands at high energy, and d–d bands around 
20000 cm-1 and just below 9000 cm-1. The Ni(II) compounds show the CT bands above 27000 cm-1 
and d-d bands at 16500 and 10000 cm-1. However, the degree of distortion from octahedral due to 
the different ligand cannot be observed for compounds 3-6. In the case of 3 and 5, the elemental 
analysis showed the presence of 1 equivalent of MeOH. Ligand field spectra can neither proof nor 
exclude that MeOH is coordinated to the Co or Ni. The diffuse reflectance spectra are depicted in 
Figures S9-S14. To learn more on the electronic structure of the 2 Cu compounds, the EPR spectra 
in the solid state were recorded (spectra are depicted in Figures S15-S16 in the supplementary 
material). The observed g values are as expected for Cu(II) [69], having g(average) values of 2.089 
and 2.087 for compounds 1 and 2, respectively; g anisotropy and hyperfine splittings are not 
resolved, most likely due to the relatively close proximity of the Cu ions in the solid state. 
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Furthermore, the 1H NMR spectra of Zn compounds 7 and 8 were performed in DMSO-d6 at 
400 MHz at 293 K (presented in Figures S17-20 in the supplementary material). The signal 
appeared at ~11.8 ppm was attributed to NH proton; the characteristic aromatic protons are 
displayed in the range of ~9-7 ppm (for details, see experimental section above). The signals show 
marked shifts when compared with the ligand “Hnor” alone. 13C NMR of 7 and 8 complexes was 
also performed at 100 MHz, which showed all the peaks in the aromatic region of ~140-110 ppm as 
expected (depicted in Figures S21 and S22, in the supplementary material). Thus, all the peaks 
were observed in accordance with the proposed structure. 
Description of the molecular structure for compound 1 
 The molecular structure of compound 1 was studied using X-ray single crystal diffraction 
analysis. Descriptive molecular and packing diagrams are presented in Figure 1 and selected 
geometrical data are summarized in Table 2. 
 
 
 
 
 
 
 
 
 
 
Figure 1: Molecular and c-axis hydrogen bonding diagrams with the used labeling scheme for 
compound 1. Two disordered positions for the O2 atom of the coordinated nitrate are shown. 
Thermal ellipsoid are at the 50% probability level and hydrogen atoms are represented as spheres 
of arbitrary radii. 
 
Table 2. Relevant bond distances (Ȧ) and angles (deg) for compound 1 
 Lengths  Angles 
Cu1-O1 2.209(3) O1-Cu1-O4    100.62(10)  
Cu1-O4   2.042(2)  O1-Cu1-O5 153.91(10) 
Cu1-O5 2.644(2) O1-Cu1-N1 92.08(11) 
Cu1-N1  2.051(3) O1-Cu1-N2  96.67(12)  
Cu1-N2 2.007(3) O1-Cu2-N3 98.71(12)  
Cu1-N3 1.992(3)  O4-Cu1-O5  53.43(8) 
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In 1, the Cu(II) is coordinated in a distorted octahedral way, by a bidentate phen, a 
monodentate Hnor, a monodentate nitrate and a chelating bidentate nitrate. The Hnor ligand 
coordinates with the pyridine nitrogen, whereas the N-H group of the ligand, donates a hydrogen 
bond (intermolecularly) to the coordinated O of the bidentate nitrate of a nearby molecule in C(7) 
first level chain motif along the [010] base vector, with an N----O contact distance of 3.02(4) Ȧ. The 
monodentate nitrate is found disordered over 2 rotational positions. The coordination mode of Hnor 
agrees with our previously found [50] binding to Ag(I) and also with the only transition-metal 
compound (Ru) known so far for this ligand [49]. Nitrates are well known to be able to coordinate in 
different modes to metal ions, be it monodentate or bidentate, and two different binding modes in 
the same compound are also known for quite some time [67]. Given the fact that the ligand has 
several bands in the 1300-1500 cm-1 wavelength range, it was not possible to discriminate between 
the possible binding modes and mixtures of them from IR. However, given the overall similarities in 
the IR spectra, we have assumed that the binding modes of the Co, Ni and Zn compounds are 
similar to that of the Cu(II) compound.  
Cytotoxic properties 
The antiproliferative properties of the ligand Hnor and the metal complexes 1-5 and 7 (with 
cisplatin used as a comparison) were assessed by monitoring their ability to inhibit cell growth using 
the classical MTT assay in human ovarian (A2780) and lung cancer (A549) cell lines. Table 3 
summarizes the obtained IC50 data, and Fig. 2 shows representative effects on cell viability for 
compound 3. Interestingly, the copper compound 1 appears to be the most effective of the series 
with similar activity as cisplatin in the A2780 cells, and being 10-fold more effective than cisplatin in 
the A549 lung cancer cell line. This latter result is remarkable since these lung cancer cells are 
resistant against cisplatin treatment. Moreover, the cytotoxic effects of 1 are already evident after 24 
h incubation (IC50 = 3.57 ± 0.98 ȝM), while cisplatin is still poorly active (IC50 = 24.2 ± 1.6 ȝM). 
Concerning the other complexes with 1,10-phenanotroline ligands, the antiproliferative activities 
followed the order 7 (Zn) > 3 (Co) >> 5 (Ni). In general, the compounds 2 and 4 (with the bipyridine 
ligand) were found less effective than their phen analogues. It should be noted that the phen ligand 
exerts itself important antiproliferative effects, followed by the bpy ligand. Instead, the free Hnor 
ligand is not toxic in both the tested cell lines (IC50 > 200 µM) (Table 3). Notably, the biological 
activity of 1 and 2 is not only due to the presence of Cu(II) ions, but to the overall compounds’ 
chemico-physical properties (e.g. hydrophilic/lipophilic balance and stability) which may lead to its 
enhanced accumulation in cancer cells. In fact, treatment of cancer cells with CuCl2 did not show 
any toxic effect at concentrations higher than 200 ȝM (Table 3). 
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Figure 2 - Effects of compound 3 on cell growth of A2780 cells. Reported data are from a single 
representative experiment. The concentration unit is in M.  
 
Afterwards, we have used Annexin V/PI flow cytometry detection to determine whether the 
selected complexes are able to induce apoptosis in A549 cells after 72 h incubation. Compounds 
were tested at different concentrations around their IC50 values (equal, below or higher). 
Representative results are reported in Fig. 3, showing that the most effective copper compound 1 
induces cell death meanly by apoptosis already at 0.5 ȝM concentration. Instead, the bpy analogue 
2 is less effective, causing comparable apoptosis only at 7 ȝM concentration. In line with the MTT 
assay results, the cobalt complexes 3 and 4 are much less efficient, inducing apoptosis by only 30% 
and 27% at a concentration of 7 and 20 ȝM, respectively.  
Mechanism of drug uptake plays a major role in their anticancer properties. In the case of 
cisplatin and other Pt(II) derivatives exact knowledge of the mechanisms governing their 
accumulation in cells is still lacking. However, among the proposed pathways, Cu transporters (e.g. 
CTR1) have been shown to be involved in the cellular import of Pt(II) chemotherapeutic agents in 
cancer cells, as well as in their resistance mechanisms [70]. In order to study transport of the 
compounds via copper transporters, the effects of addition of “free” Cu(II) ions to the cell culture 
medium were also evaluated. Thus, we co-administered complexes 1-5 and 7 with non-toxic 
concentrations of CuCl2 (a competitor for transport via hCTR1), at the highest non-toxic dose (20 
ȝM), and evaluated the effects on proliferation after 24 or 72 h incubation. If the uptake of the metal 
compounds goes via the same route as for Cu2+, then we would expect a reduced toxic effect due to 
reduced uptake of metal compounds in cancer cells. However, as it is shown in Table 3, the addition 
of CuCl2 increases the activity of both copper and cobalt compounds. This effect is especially 
dramatic for the Co2+ compound 3 in both cell lines, where IC50 values change from the compound 
being not active to one of the most potent of the series (see Figure 2 above). Given the fact that 
Cu(II) is a very strong ligand binder, this would suggest that in these cases the Cu(II) compound is 
largely responsible for the observed activity. 
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Figure 3. Representative flow cytometry scheme of apoptotic A549 cells stained with Annexin V-
APC/PI. Cells were treated with compounds 1-4 at different concentrations for 72 h. The results are 
representative of three independent experiments. 
 
Certainly, according to our results, metal transport via copper transporters can be excluded. 
However, in order to explain the effects of CuCl2 addition on cell proliferation, we hypothesized that 
upon addition of Cu2+ ions either the copper complexes 1-2 are stabilized, or the ligands of the 
metal compounds 3-5 and 7 prefer binding to copper with respect to their own metal ions. In the 
latter case, replacement of the metal centre with copper would give rise to the most stable Cu 
complexes in solution, with enhanced antiproliferative effects. Concerning the Cu complexes 1-2, 
the addition of copper renders the compounds more stable to hydrolysis and also may enhance 
their biological activity. To prove this hypothesis, CuCl2 was added to solutions of each metal 
complex in a 1:4 ratio and the absorbance of the samples was recorded at different time points over 
24 hours by UV-visible spectroscopy. Representative absorption spectra for complex 4 are reported 
in Fig. 4. As it can be seen from the obtained data, formation of a new band between 700-900 nm 
could be detected already after 30 min, corresponding to the absorption band of the related copper 
complex 2. Further incubation of the solution, did not increase the intensity of the band. 
Interestingly, the effects of copper addition on the cytotoxic effects of the various metal 
compounds follow the expectations according to the Irving-Williams series [71], which refers to the 
relative stabilities of complexes formed by a metal ion. For high-spin complexes of the divalent ions 
of first-row transition metals, the stability constant for the formation of a complex follows the order: 
Mn(II) < Fe(II) < Co(II) < Ni(II) < Cu(II) > Zn(II). Thus, the addition of Cu2+ to complexes 1-5 and 7 
should induce metal exchange and formation of the most stable copper complex. The propensity of 
this reaction to occur should follow the order Co(II) > Ni(II) > Cu(II) < Zn(II). This is reflected not only 
by the UV-vis data but also by the trend in the cytotoxic effects. In fact, the Co complexes are those 
that have the highest increase in antiproliferative activity after co-incubation with CuCl2 (ca. 10-fold: 
IC50 of 3 = 12.70 ± 0.97 ȝM and of (3 +CuCl2) = 0.83 ± 0.29 ȝM, respectively; see Figure 2). 
Noteworthy, the value for the (3 +CuCl2) is comparable to the IC50 calculated for 1 (IC50 = 1.88 ± 
0.21 ȝM), consistent with the formation of Cu complexes in the cell culture medium. It is worth 
 13 
mentioning that metal complex instability in aqueous media, favored by the addition of Cu(II) ions, 
may also affect the concentration of “free” phen ligand which is also toxic. 
 
Table 3. IC50 of the metal compounds 1-5 and 7, and related ligands, determined with and without 
co-incubation with 20 µM CuCl2 in human ovarian carcinoma A2780 and human lung carcinoma 
A549 cells. Values for cisplatin and CuCl2 are reported for comparison. 
                                                                    IC50 (ȝM)[a] 
                                           A2780                                                 A549 
Compound      24 h     72 h    24 h   72 h 
1 
1 + CuCl2 
3.57 ± 0.98 
1.94 ± 0.51* 
1.88 ± 0.21 
0.83 ± 0.10* 
9.40 ± 0.36 
3.50 ± 0.44* 
3.03 ± 0.12 
2.40 ± 0.36 
2 
2 + CuCl2 
25.1 ± 4.9 
13.87 ± 0.72* 
9.85 ± 1.38 
6.25 ± 1.58* 
53.47 ± 3.01 
43.3 ± 4.5* 
22.05 ± 2.91 
17.7 ± 2.1** 
3 
3 + CuCl2 
>100 
1.87 ± 0.97 
12.70 ± 0.97 
0.83 ± 0.29* 
>200 
5.27 ± 1.89 
7.70 ± 3.64 
2.50 ± 0.36** 
4 
4 + CuCl2 
5 
5 + CuCl2 
7 
7 + CuCl2 
Free phen 
Free bpy 
Free Hnor 
CuCl2 
cisplatin 
>100 
44.9 ± 3.0 
- 
- 
- 
- 
- 
- 
> 200 
> 200 
24.2 ± 1.6 
41.9 ± 7.8 
9.18 ± 1.83* 
96.1 ± 4.2 
35.6 ± 5.8 
1.26 ± 0.07 
1.23 ± 0.01 
3.70 ± 1.50 
10.70 ± 1.80 
> 200 
> 200 
1.9 ± 0.6 
>200 
>200 
- 
- 
- 
- 
- 
- 
> 200 
> 200 
34.7 ± 2.5 
79.2 ± 14.0 
38.3 ± 2.0* 
- 
- 
- 
- 
3.72 ± 1.51 
11.50 ± 0.95 
> 200 
> 200 
8.0 ± 0.5 
 Values are the average ±SEM of at least three independent experiments, *p<0.05, **p>0.07. 
  
Similar effects are observed for the Co-bpy analogue 4. The effect of CuCl2 on the nickel 
complex 5 is more moderate (only ca. 3-fold increase in potency) in accordance with the higher 
stability of the compound with respect to metal substitution. Although reactivity of the zinc complex, 
7, with CuCl2 could also be observed via absorption spectroscopy, since the zinc complex, 7,  is 
already per se very cytotoxic, marked effects induced by addition of CuCl2 could not be recorded, 
and we cannot even exclude that 7 may be exerting important effects per se. Nevertheless, it is also 
possible that metal substitutions may also occur in vivo in the presence of physiological copper ions 
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already available in the cell culture medium. Finally, just as expected the biological effects of the 
copper complexes, 1-2 do not vary substantially in the presence of CuCl2. 
 
 
Figure 4. UV-Absorption spectra of the Co compound 4 after addition of CuCl2 (1:4 stoichiometric 
ratio) recorded at different times over 24 h. 
  
Concluding Remarks  
Heterocyclic ligands with N-donor groups and nearby N-H groups have shown to be an 
interesting ligand series to be used in binding studies with metal ions where the coordination to 
transition metal ions can also be influenced by hydrogen bonding of the N-H group to e.g. anions; 
as mentioned, such a phenomenon is already known and described [55]. As for pyrazoles, for all the 
reported compounds, intramolecular H bonds are also visible, as shown by XRD and deduced from 
IR; while intermolecular hydrogen bonding to the anion must also occur. Concerning the anticancer 
properties, it appears that the marked antiproliferative activity of the copper complexes 1-2 and of 
the zinc compound 7 has to be ascribed to at least the presence of significant amounts of the metal 
in combination with both ligands. Overall, this trend in activity is in accordance with previously 
reported studies on similar first-row transition metal compounds [61]. While transport of the reported 
compounds via copper transporters may be excluded, our results allowed to identify the most active 
divalent metal complexes within the first-row transition metals, which can be related to the order of 
stability within the Irving-Williams series. Further studies are necessary to identify the pathways 
leading to apoptosis. However, it is worth mentioning that, inside the living cell, metal binding and 
redox events enter into an exciting, and highly complicated interplay, often resulting in extensive 
cellular signaling pathways and control networks. Thus, the application of coordination compounds 
of endogenous metal ions may be even more relevant to induce important intracellular alterations at 
physiological concentrations. Although the mechanism of antiproliferative activity is not well 
established for kinetically labile metal ions, the observed biological effects of these complexes, also 
as a result of the competition with other endogenous metal ions for ligand binding, appears as 
promising.  
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Table of less common abbreviations 
hCTR1 Human copper transporter 1 
Hnor 9H-Pyrido[3,4-b]indole 
DMEM Dulbecco's Modified Eagle Medium 
RPMI Roswell Park Memorial Institute 
FACS Fluorescence-activated cell sorting 
PI Propidium iodide 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
bpy 2,2’-bipyridyl 
phen 1,10-phenanthroline 
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Appendix A. 
Supporting information. 
Crystallographic data (excluding structure factors) for the structure reported in this paper 
have been deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication no. CCDC1415868. Copies of available material can be obtained, free of charge, on 
application to the Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-
336033 or Email: deposit@ccdc.cam.ac.uk.  
The supplementary information connected with this manuscript contains IR spectra (Figures 
S1-S8); ligand-field diffuse reflectance spectra for the Cu, Co and Ni compounds (Figure S9-S14), 
and the EPR spectra for compounds 1 and 2 (Figure S15-S16). 1H NMR spectra of compound 7 and 
8 (Figure S17-S20). 13C NMR spectra of compound 7 and 8 (Figure S21-S22).  Also the cif file and 
the checkcif files are available as supplementary information. 
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